MedPath

calcipotriene and betamethasone dipropionate

These highlights do not include all the information needed to use safely and effectively. See full prescribing information for . Initial U.S. Approval: 2006

Approved
Approval ID

1359f4b2-60c9-42c9-8b25-9ef955ffeae5

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 1, 2023

Manufacturers
FDA

Padagis Israel Pharmaceuticals Ltd

DUNS: 600093611

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

calcipotriene and betamethasone dipropionate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code45802-889
Application NumberANDA212367
Product Classification
M
Marketing Category
C73584
G
Generic Name
calcipotriene and betamethasone dipropionate
Product Specifications
Route of AdministrationTOPICAL
Effective DateAugust 1, 2023
FDA Product Classification

INGREDIENTS (6)

.ALPHA.-TOCOPHEROL, DL-Inactive
Code: 7QWA1RIO01
Classification: IACT
HYDROGENATED CASTOR OILInactive
Code: ZF94AP8MEY
Classification: IACT
MINERAL OILInactive
Code: T5L8T28FGP
Classification: IACT
BETAMETHASONE DIPROPIONATEActive
Quantity: .5 mg in 1 g
Code: 826Y60901U
Classification: ACTIM
BUTYLATED HYDROXYTOLUENEInactive
Code: 1P9D0Z171K
Classification: IACT
CALCIPOTRIENE MONOHYDRATEActive
Quantity: 50 ug in 1 g
Code: S7499TYY6G
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

calcipotriene and betamethasone dipropionate - FDA Drug Approval Details